Keyword Search Year None20222021202020192018201720162015201420132010 Date Title Media 11/14/22 Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update 11/08/22 Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 10/03/22 Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer 09/06/22 Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference 08/15/22 Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights 08/08/22 Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 07/13/22 Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences 07/06/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer 06/23/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma 06/14/22 Calithera Biosciences Announces 1-for-20 Reverse Stock Split 05/17/22 Calithera to Present at the H.C. Wainwright Global Investment Conference 05/10/22 Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights 05/03/22 Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022 04/08/22 Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds 03/31/22 Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights 03/30/22 Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock 03/29/22 Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock 03/24/22 Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022 03/08/22 Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting 02/16/22 Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference 01/05/22 Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
